绝经后骨质疏松症的预防和药物联合序贯治疗

被引:28
作者
孙国平 [1 ]
罗选翔 [2 ]
潘彬 [2 ]
机构
[1] 南京市高淳人民医院
[2] 徐州医科大学
关键词
骨; 绝经后; 骨质疏松症; 骨折; 预防; 药物;
D O I
暂无
中图分类号
R580 [];
学科分类号
摘要
背景:绝经期后的妇女由于雌激素水平下降导致骨吸收迅速增加,造成骨吸收和形成之间的不平衡,增加了骨质疏松和相关部位骨折的风险。然而,目前的临床防治并不足以抑制长期的骨丢失和不断增加的骨折风险。近年来,针对绝经后骨质疏松症及时有效的预防和抗骨质疏松药物序贯联合治疗已成为必然趋势。目的:就绝经后骨质疏松症的预防和抗骨质疏松药物治疗的相关文献进行总结,介绍绝经后骨质疏松症的临床预防措施和常见的抗骨质疏松药物联合序贯治疗进展。方法:作者于2020年1月应用计算机检索2009年1月至2019年12月中国期刊全文数据库CNKI、万方和PubMed数据库的相关文章,中文检索词"绝经后骨质疏松症,预防,药物,治疗";英文检索词"Postmenopausal osteoporosis,prevention,drug therapy,medication",根据纳入标准及排除标准摘选41篇文章进行分析讨论。结果与结论:①绝经后妇女要及时进行骨密度测试,通过改变饮食结构和生活方式进行预防,以降低骨折风险;②与单一药物相比,联合序贯疗法可以更有效地治疗绝经后骨质疏松症,对绝经后骨质疏松症的治疗具有深远的意义。
引用
收藏
页码:5385 / 5390
页数:6
相关论文
共 22 条
[1]
骨质疏松症治疗药物的分类与用药选择 [J].
王建华 .
中华老年骨科与康复电子杂志, 2019, 5 (05) :297-300
[2]
原发性骨质疏松症诊疗指南(2017) [J].
夏维波 ;
章振林 ;
林华 ;
金小岚 ;
余卫 ;
付勤 .
中国骨质疏松杂志, 2019, 25 (03) :281-309
[3]
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study [J].
McClung, Michael R. ;
Brown, Jacques P. ;
Diez-Perez, Adolfo ;
Resch, Heinrich ;
Caminis, John ;
Meisner, Paul ;
Bolognese, Michael A. ;
Goemaere, Stefan ;
Bone, Henry G. ;
Zanchetta, Jose R. ;
Maddox, Judy ;
Bray, Sarah ;
Grauer, Andreas .
JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (08) :1397-1406
[4]
A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis [J].
Liu, Gui-Feng ;
Wang, Zong-Qiang ;
Liu, Lin ;
Zhang, Bu-Tian ;
Miao, Ying-Ying ;
Yu, Shao-Nan .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (06) :4469-4481
[5]
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk [J].
Mignot, M. A. ;
Taisne, N. ;
Legroux, I. ;
Cortet, B. ;
Paccou, J. .
OSTEOPOROSIS INTERNATIONAL, 2017, 28 (12) :3431-3438
[6]
Prospect of Combination and Sequential Therapies for Postmenopausal Osteoporosis [J].
Liu, Hao ;
Li, Binbin .
CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (41) :6251-6255
[7]
Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.[J].Yang Shen;Dona L. Gray;Dorothy S. Martinez.Endocrinology and Metabolism Clinics of North America.2016, 1
[8]
Treatment needs and current options for postmenopausal osteoporosis [J].
Gennari, Luigi ;
Rotatori, Stefano ;
Bianciardi, Simone ;
Nuti, Ranuccio ;
Merlotti, Daniela .
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) :1141-1152
[9]
Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial [J].
Leder, Benjamin Z. ;
Tsai, Joy N. ;
Neer, Robert M. ;
Uihlein, Alexander V. ;
Wallace, Paul M. ;
Burnett-Bowie, Sherri-Ann M. .
JOURNAL OF CLINICAL DENSITOMETRY, 2016, 19 (03) :346-351
[10]
The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women [J].
Komm, Barry S. ;
Morgenstern, Diana ;
Yamamoto, Luis A. ;
Jenkins, Simon N. .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (06) :769-784